Company intelligence / Profile preview

Plasmavitta

Ownership: Private
Development stage: Commercial

Overview

Plasmavitta operates as an active human blood plasma donation center network. It collects human blood plasma from donors to be processed into pharmaceuticals by third-party manufacturers. There are no clinical results attributable to the company itself as it does not develop therapeutic products

Modalities: Plasma-derived therapy (as a supplier/collector; not a developer/manufacturer)Not directly involved in drug development modalities like Small molecule or Monoclonal antibody
Industry: Non-Academic Healthcare

Drug pipeline

3 assets

Platelet-rich plasma (PRP)

Commercial

Indications: Orthopedic conditions, Sports medicine

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Plasmavitta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plasmavitta.

Explore the full profile